This time it’s Amgen under fire. Yesterday’s WSJ talks about the fading star and the case after yet another pharma company that depends on a blockbuster with little in the pipeline. On top of that, the good ‘ol Pfizer is having more trouble with Celebrex. A consumer group (Public Citizen) demands that FDA orders Pfizer to withdraw a new ad TV. They claim that the add misinforms consumers about the health risks associated with the drug. Bur you be the judge, just watch the add. The Health Blog has some interesting comments, especially the second one down is worth to read.
But I can’t talk about big bad pharma without mentioning Merck. Now they face a tough road ahead. The FDA said that that new painkillers should “fill an unmet medical need for patients who have no other “relatively safer” alternatives.” Translation: good chance that Vioxx successor won’t be approved for a long while.
So who am I missing? Oh yes, GlaxoSmithKline pulls a drug from it’s pipeline – increased heart attack risk – and causes its partner’s shares to drop 57%. I am sure that if I really wanted, I could find a disaster story for every big bad pharma company out there. I guess not a good time to be in pharma. Then again, it’s not a good time to be an employee for Citygroup either…
Song of the day:
Loading ...